One Step Forward, Two Steps Back: Regulatory Reform May Be Tougher On CMS Than On FDA
This article was originally published in The Pink Sheet
Executive Summary
President-Elect Trump is putting new meaning in the catch phrase “doubling down”: promising an executive order to require agencies to withdraw two old regulations any time they issue a new one. That may be a big challenge for CMS – and also complicate some aspects of FDA’s activities.
You may also be interested in...
Rulemaking Process Flawed, But Making Monograph Rules Still Needs Funding
The monograph program was "instituted really many, many decades ago. We've been trying to implement it since," says CDER Director Janet Woodcock. "We haven't had a much bigger pie to play with, so that's been one constraint that we've had to deal with," says center budget chief Donal Parks.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.